The Hits Keep Rolling for BIEL's FDA Clearance, Rh
Post# of 7805
(Total Views: 454)
Posted On: 02/27/2020 9:33:47 AM
The Hits Keep Rolling for BIEL's FDA Clearance, Rheumatology Network
In an article about new NSAIDs the first two paragraphs are given to ActiPatch.
More New NSAIDs for Arthritic Pain Relief
Rheumatology Network Editorial Staff
February 27, 2020
"The U.S. Food and Drug Administration (FDA) has expanded the indication of the over-the-counter pain reliever ActiPatch (BioElectronics Corp.) to include all musculoskeletal pain. Currently, ActiPatch, which is a pulsed shortwave therapy, is recommended for the treatment of pain from knee osteoarthritis and plantar fasciitis."
"In a clinical trial published online in Future Medicine on May 29, 2019, of 174 patients with chronic pain who were treated with ActiPatch for seven days, all patients experienced pain relief by an average of 4.3 visual analog scale points. The company received 510(k) clearance from the FDA earlier this month."
https://www.rheumatologynetwork.com/news/more...ain-relief
In an article about new NSAIDs the first two paragraphs are given to ActiPatch.
More New NSAIDs for Arthritic Pain Relief
Rheumatology Network Editorial Staff
February 27, 2020
"The U.S. Food and Drug Administration (FDA) has expanded the indication of the over-the-counter pain reliever ActiPatch (BioElectronics Corp.) to include all musculoskeletal pain. Currently, ActiPatch, which is a pulsed shortwave therapy, is recommended for the treatment of pain from knee osteoarthritis and plantar fasciitis."
"In a clinical trial published online in Future Medicine on May 29, 2019, of 174 patients with chronic pain who were treated with ActiPatch for seven days, all patients experienced pain relief by an average of 4.3 visual analog scale points. The company received 510(k) clearance from the FDA earlier this month."
https://www.rheumatologynetwork.com/news/more...ain-relief
(3)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼